In the SOFT trial of premenopausal women with HR-positive breast cancer, findings indicated that recurrence rates in women under 35 who were estrogen receptor-positive improved after receiving ovarian suppression with either tamoxifen or with the aromatase inhibitor exemestane. Francis emphasizes that this is a population of women who demonstrate poor outcomes, and ovarian suppression may be an option to improve survival.

In the SOFT trial of premenopausal women with HR-positive breast cancer, findings indicated that recurrence rates in women under 35 who were estrogen receptor-positive improved after receiving ovarian suppression with either tamoxifen or with the aromatase inhibitor exemestane. Francis emphasizes that this is a population of women who demonstrate poor outcomes, and ovarian suppression may be an option to improve survival.